Research

rs3135506 — APOA5 S19W

Triglyceride metabolism - affects fasting triglyceride levels and cardiovascular risk

Strong Risk Factor

Details

Gene
APOA5
Chromosome
11
Risk allele
C
Protein change
p.Ser19Trp
Consequence
Missense
Inheritance
Codominant
Clinical
Risk Factor
Evidence
Strong
Chip coverage
v3 v4 v5

Population Frequency

GG
88%
CG
11%
CC
1%

Ancestry Frequencies

european
6%
latino
6%
african
2%
south_asian
2%
east_asian
1%

APOA5 — Triglyceride Metabolism

APOA5 (Apolipoprotein A5) plays a key role in regulating triglyceride levels. Discovered in 200111 Discovered in 2001
Pennacchio et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 2001
through comparative sequencing of the APOA1/C3/A4 gene cluster, APOA5 was found to strongly influence plasma triglyceride concentrations in both humans and mice.

The Mechanism

The S19W variant (rs3135506) causes a serine-to-tryptophan substitution at position 19 (p.Ser19Trp) in the signal peptide22 The signal peptide is a short amino-acid sequence that directs a newly made protein for secretion out of the cell of the APOA5 protein. This disrupts the signal peptide function, reducing APOA5 secretion into the bloodstream by approximately 50%. Since APOA5 normally lowers triglycerides by stimulating lipoprotein lipase activity and inhibiting VLDL production, reduced secretion leads to higher triglyceride levels.

The Evidence

The ICARIA study33 ICARIA study
Loria et al. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia. BMC Med Genet, 2010
demonstrated that APOA5 S19W carriers have an independent, additive triglyceride-raising effect. Carriers of the rare allele show significantly higher levels of large VLDLs (+133%) and small dense LDLs (+34%), creating a proatherogenic lipid profile.

Guardiola et al.44 Guardiola et al.
Guardiola et al. APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis, 2015
confirmed that this variant predisposes carriers to atherogenic dyslipidemia and subclinical atherosclerosis — measurable thickening of artery walls even before symptoms appear.

High triglycerides are an independent risk factor for cardiovascular disease and pancreatitis55 Very high triglycerides (above roughly 500 mg/dL) can trigger acute pancreatitis, a serious inflammation of the pancreas.

Practical Implications

The C allele is found in about 6% of Europeans and up to 14% of Hispanics, but is rare (<2%) in East Asian and African populations. Dietary interventions — especially limiting refined carbohydrates and increasing omega-3 intake — are the primary management strategy.

Interactions

Triglyceride-raising effects are additive when combined with variants in LPL and APOE genes. If you also carry APOE E4 (rs429358), your overall cardiovascular risk is compounded.

Nutrient Interactions

omega-3 fatty acids increased_need
refined carbohydrates altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

GG “Normal Triglycerides” Normal

Normal triglyceride metabolism

You have normal APOA5 function, shared by about 88% of Europeans. Your triglyceride levels respond typically to diet and lifestyle.

CG “Elevated Triglyceride Risk” Intermediate Caution

One variant - higher triglyceride tendency

You carry one copy of the S19W variant, found in about 11% of Europeans. This reduces APOA5 secretion by approximately 50%, leading to higher triglyceride levels. Carriers show significantly higher levels of proatherogenic large VLDLs and small dense LDLs.

CC “High Triglyceride Risk” High Risk Warning

Two variants - significantly higher triglycerides

You have two copies of the S19W variant, a rare genotype (~1% of Europeans). You have a strong genetic tendency toward higher triglyceride levels due to severely reduced APOA5 secretion. This significantly increases your risk of cardiovascular disease and potentially pancreatitis with very high triglyceride levels.

Key References

PMID: 11588264

Pennacchio et al. — discovery of APOA5 as a novel apolipoprotein influencing triglycerides in humans and mice (Science 2001)

PMID: 20429872

Loria et al. — ICARIA study showing additive triglyceride-raising effects of APOA5 + LPL + APOE variant combinations

PMID: 25770687

Guardiola et al. — APOA5 variants predispose to atherogenic dyslipidemia and subclinical atherosclerosis

PMID: 20304614

Mattei et al. — S19W effects on triglycerides influenced by sex and menopause status

PMID: 32043985

Sharma et al. — comprehensive 15-year review of APOA5 genetic epidemiology and triglyceride regulation